# Subject index Volume 2 (1991).

cachectic patients 196 ablative therapy S2: 147 cancer 19, 67, 141 ABVD S2: 73 chemotherapy 517 **ACNU 767** communication 273 acute leukemia 251, 745 diagnosis 565 acute lymphocytic leukemia 33 patients 610 acute myelocytic leukemia 441 risks 395, 559, 629 acute promyelocytic leukemia 405 treatment 216, 565 adenocarcinoma of pancreas 153 treatment and caregiving 511 adjuvant endocrine therapy 343 trends 395 adjuvant MVPP S2: 49 capillary microscopy 310 adjuvant therapy 401, 641 carboplatin 115, 131, 607 adrenal glands and lymphoma 40 carcinoma of unknown origin 519 adverse reactions 154 cardiac failure S2: 77 age 297 cardiopulmonary toxicity S2: 73 aggressive lymphomas S2: 171 cardiotoxicity 383 AIDS 289, S2: 191 cardiovascular disease 709 AILD S2: 157 CD30-positive lymphoma 40 air pollution 265 CD8 579 **CEA 409** all-trans-retinoid acid 234 alpha-interferon 759 cell adhesion molecules S2: 107 alternating chemotherapy S2: 55 cell lines 541 amphotericine B 141 cell surface peptidases S2: 107 cerebral dysfunction 769 anaplastic large-cell lymphoma S2: 33, S2: 163 anthracyclines 719 cerebral metastases 15 cervical vertebra 521 anti-idiotype antibodies S2: 115 antiemetic 223, 517, 607, 681 chemoprevention 446 chemotherapy 15, 33, 41, 141, 153, 203, 229, 310, 423, 565, 667, trials 107 antisteroidal agents 183 687, 751, 755, S1: 9, S1: 17 **APACHE II 571** chemotherapy effects 709 assessment of necrosis 489 chemotherapy-induced emesis 107, 681 chemotherapy induced leucopenia 69 ATL S2: 157 autologous bone marrow transplantation 57, 645, S1: 47, S1: 51, chemotherapy-radiotherapy S2: 137 childhood 745 S2: 1, S2: 39, S2: 67, S2: 131, S2: 147, S2: 181 autopsy 130 chromogranin A 355 chromosomal translocations S2: 9 chronic disease 511 CHVmP+VB 431 B cell chronic lymphocytic leukaemia S2: 107 B-cell neoplasia 335 cimetidine 517 cisplatin 115, 131, 197, 212, 217, 223, 379, 519, 521, 755 basic sciences 565 cisplatin plus 5-fluorouracil 751 batanopride 154, 681 BEAC S1: 57 cisplatin plus etoposide 687 biochemical modulation 469 clinical epidemiology 395 biological response modifiers 141 clinical trials 461, 597, 681 biology of lymphomas S2: 1, S2: 9 clonal excess 739, S2: 99 bleomycin 379 clonogenic assay 72 BMY-25801 154 coagulation disorders 67 colorectal cancer 409, 641, 673, 687, 759, 767 bone marrow infiltration S2: 107 combination chemotherapy 231, 310, 365, 519, 521, S1: 25 bone marrow involvement 13 bone marrow S2: 39 combination cisplatin-carboplatin 123 bone marrow transplantation S2: 67 combined carboplatin/etoposide treatment 361 breast cancer 13, 47, 183, 269, 273, 343, 401, 417, 446, 461, 481, combined modality therapy 25 495, 521, 575, 663, 709 comparative analysis 745 buserelin 303 composite lymphoma S2: 83 conservative treatment 347 continuous infusion 223, 691, 751 C-erbB-2 47 controlled trial 41 CA 19.9 409 cyclosporin-A 305

cytokines 251 cytoreductive regimens S1: 47 cytosine arabinoside 441 cytotoxic drugs 325

# D

death rate 191
4-demethoxydaunorubicin 605
dexamethasone 517
DHAP S1: 57
diagnosis 355
DICE S1: 43
differentiation 55
diffuse large-cell lymphoma 365
DLCL with sclerosis 733
DNA repair 325
doxorubicin 695
drug distribution 63
drug resistance 93, 325, 535, S2: 151

# E

**EAP 310** EBV S2: 33, S2: 157 ECOG performance status 437 educational program 9 elastic sleeve 575 electrically stimulated drainage 575 empirical antibiotic regimen 485 epidemiology 265, 395, 405, 559, S2: 23 epirubicin 137, 663 Epstein-Barr virus S2: 23 ESMO certification 9 estrogen replacement therapy 709 estrogens 169 etoposide 63, 197, 519, S1: 47 Ewing's sarcoma 521 extranodal 501 extremity osteosarcoma 489

# R

F fenretinide 446 fetal kidney 55 fever 485 first-generation chemotherapy 431 flavone acetic acid (FAA) 145 5-fluorouracil 153, 229, 379, 383, 469, 519, 521, 641, 691, 759 folinic acid 229 follicular lymphomas 605, S2: 93, S2: 123, S2: 131, S2: 141, S2: 147 fotemustine 377

# G

gastric cancer 229, 310, 751 gastric metastases 694 gene expression 335 germ cell tumors 197, 771 glucocorticoid receptor 541 glucocorticoid resistance 541 GM-CSF 522 growth factors 183, S2: 151, S2: 207

# H

head and neck tumors 379 hematopoietic growth factors 251, 645

high-dose chemo-radiotherapy 645 high-dose DTIC 307 high-dose metoclopramide 223 high-grade lymphoma 431 histologic progression S2: 123 histology 771, S2: 123 histopathology 355 HIV S2: 201 HIV infection 289 HIV-related lymphomas 585 Hodgkin's disease 25, 297, 423, 579, 585, 645, S1: 1, S1: 9, S1: 17, S1: 47, S1: 51, S2: 1, S2: 23, S2: 29, S2: 33, S2: 39, S2: 43, S2: 55, S2: 67, S2: 73, S2: 77, S2: 83, S2: 201 home treatment 485 homosexual men 373 HTLV-I S2: 157 5-HT<sub>3</sub>-antagonist 154 human brain tumors 63 human malignancies 541 human xenografts 72 hybrid regimen S2: 55 5-hydroxytryptamine receptor antagonist 681 hypotension 154

# I

IBL-like T-lymphoma S2: 157 ICU 571 ifosfamide 151, 153, 197 illness progression and caregiving 511 immuno-chemotherapy 759 immunogenotyping 629 immunohistochemistry 55 immunosuppression S2: 191 immunotherapy 67, 251, S2: 115 induction chemotherapy 347 intensification 203 interferon S2: 131, S2: 141 interleukin-2 67 interleukin-2 receptors S2: 43 interleukin-6 S2: 207 interleukins 251 intermediate-grade 431 intermediate-/high-grade non-Hodgkin's lymphomas S1: 33 intestinal lymphomas S2: 163 intra-interobserver variability 437 intralesional therapy 769 intraperitoneal administration 217 intrapleural treatment 213 intravenous drug users 373, S2: 201 invasive bladder cancer 137 iododoxorubicin 727

# K

Kaposi's sarcoma 234, 373, 609 Karnofsky performance status 437 Ki-1 antibody S2: 163

# L

LAK cells 67 large-cell anaplastic lymphomas S2: 219 large-cell lymphomas S2: 213 late recurrence 382 leucovorin 379 leucovorin + 5-FU vs. 5-FU 673 leukocyte-lymphocyte ratio 196 **LHRH 303** liposomes 141 liver metastases 663, 769 localized disease 739 long-term results 269, S2: 29 long-term toxicity S2: 77 lorazepam 223 low grade non-Hodgkin's lymphoma 655 lung cancer 41, 265, 694 lymph node involvement 269 lymphoblastic lymphoma 745, S2: 181 lymphoma 93, 501, S1: 51, S2: 115, S2: 187, S2: 191

MACOP-B chemotherapy 733, S1: 17 magnetic resonance imaging S2: 39 malignant lymphoma 443 malignant melanoma 377 malignant pleural effusion 213 mammary gland 169 mediastinal irradiation S2: 73 mediastinal tumour 771 medroxyprogesterone acetate 495 megestrol therapy 401 membrane transport 635 menopause 709 menstrual cycle 269 merkel cell tumor 522 meta analysis 461 methotrexate 769 micrometastases 13 mitomycin 153 mitomycin C 769 mitoxantrone 71, 213 moderately-emetogenic chemotherapy 681 molecular biology 635, S2: 23, S2: 93 molecular cancer diagnosis 629 molecular diagnostic tools 629 molecular tumour classification 629 MOPP/ABV S1: 17 MOPP-ABVD S2: 55 multi-drug resistance 93, 305, 325, 443, 635 multiple choice examination 9 muscle 501 myeloma 191 myelomonocytic antigens S2: 107

# N

nausea 223 neoadjuvant 137 nephroblastoma 55 neu 169 Neuron Specific Enolase 355 neurotoxicity 212 neutropenia 485 new-drug development 72 nifedipine 443 NK-LAK activity 145 non-Hodgkin's lymphoma in Hodgkin's disease S2: 83 non-Hodgkin's lymphomas 156, 289, 365, 382, 431, 585, 605, 739, S1: 17, S1: 31, S1: 33, S1: 37, S1: 47, S1: 57, S2:1, S2: 9, S2: 99, S2: 171, S2: 177, S2: 181

oncogenes S2: 9 oncology patients 571 ondansetron 607 operable breast carcinoma 347 oral carmofur 765 osteoporosis 709 ovarian cancer 71, 131, 231, 281, 607, 691, 755 ovarian irradiation 343

overview 461

P-glycoprotein 55, 635 palliative care 445, 693 pancreas carcinoma 765 pathogenesis S2: 23, S2: 191 patient satisfaction 273 pediatric lymphomas S2: 219 peptides 183 peripheral blood 739 peripheral T-cell lymphomas S2: 163 pharmacokinetic studies 217 phase I trial 115, 123, 217, 589 phase II trial 71, 443, 689, 719, 727, 751, 767, 772 phenitoin 443 placebo 213 platinum 535 analogs 589 -based 203 -DNA adduct 115 polymerase chain reaction S2: 93 poor prognosis teratoma 203 portents of suicide 19 postmastectomy lymphedema 575 postmenopausal patients 495 prednimustine 755

preoperative chemotherapy 489 prevention 559 primary chemotherapy 417 progestagen therapy 401 prognosis 297, 655, 739 prognostic factors 196, 281, 365, 423, 579, 667, S2: 1, S2: 43, S2: 99, S2: 107, S2: 123, S2: 131, S2: 157, S2: 171, S2: 213 prognostic index S2: 213 prolonged hormonotherapy 481

ProMACE-CytaBOM S1: 33 prostate cancer 303 prostatic cancer 183 protein kinase C 635 protocol design 93 proton relaxation times S2: 39 PSIA-IIB HD S2: 49 psychological adjustment 597 pulmonary adenocarcinoma 355 pulmonary toxicity S2: 77

quality assessment 130 quality of care 273 quality of life 597, 693 quality-of-life assessment 417

radioimmunolocalization 409 radioimmunotherapy S2: 187 radioisotopes S2: 187 radiolabeled antibody S2: 187 radiotherapy 15, 667 randomized trials 575, S2: 177 ras 169

receptor activation 541 receptor status 269

recombinant human granulocyte-macrophage colony stimulating factor 69

recurrent colonic carcinoma 409
recurrent head and neck cancer 151
recurrent lymphomas S1: 25, S1: 31
Reed-Sternberg cells S2: 33
refractory lymphomas S1: 25, S1: 43
relapsed Hodgkin's disease 505
renal cell carcinoma 55, 305, 443
response-adapted strategy S2: 177
10yr results S2: 49
rubidazone 441

S-phase 47 salvage regimens S1: 31 salvage therapy S1: 1, S2: 67 screening 535 second cancers S2: 77 second-generation chemotherapy 431 second malignancies in HD S2: 83 secondary non-Hodgkin's lymphoma S2: 83 severe toxicity 310 small-cell 41 small cell lung cancer 361, 772 soft tissue sarcomas 307, 689 stage I-II low grade lymphoma S2: 137 stomatitis 695 suicide 19, 610 sulofenur 772 survival 33, 196, S2: 29, S2: 191

symptom control 19

T cell lymphoma S2: 151 tamoxifen therapy 401, 481, 495 teniposide 63, 217 terminal patients 693 testicular cancer 197 TGFα 169 therapy S2: 191 third-generation regimens S1: 37 thyroid gland 156 **TNFα 141** total lymphoid irradiation S2: 67 transformation 169 translocation (14;18) S2: 93 treatment 745, 751 guidelines 216 trimetrexate 689 tumor burden 25 tumor marker scintigraphy 409 tumor progression S2: 115 tumour models 535

vaccination S2: 115
VACOP-B S1: 17
validation 597
variable genes S2: 115
vascular toxicity 310
verapamil 71
vinblastine 443
vulvar involvement 609

W weekly chemotherapy 505

Z zeniplatin 589

# Author index Volume 2 (1991) \_

Aapro M 377 Abad A 153 Abbott RR 571 Abbruzzese JL 519 Achterrath W 361 Agarossi A 609 Aguado M 443, 585 Ahmedzai S 445 Aitini E 673 Aiuti F 373 Åkerman M S2: 99 Al-Faraj A 517 Al-Ghamdi MS 517 Al-Idrissi HY 517 Al-Khatti AA 517 Alaerts P 589 Albanell J 310 Alberto P 9 Alerci M 123 Alessi E 373 Alevizakos N 769 Ali NM 137 Allavena P 145 Allen P S2: 137 Alonso MC 495 Alvarez I 409 Amadori S 365 Anagnostopoulos I S2: 33 Anbazhagan R 47 Anders CH S1: 25 Andersen E 223 Anderson H 739, S2: 49 Andria ML S2: 115 Andrieu J-M 289 Anglada L 495 Antón LM 751 Ardizzoni A 377 Armengaud M 289 Armitage JO 617, S1: 37, S2: 171, S2: 213 Arnott S S2: 147 Athanassiou A 769 Averous S 234 Avril A 347

B
Bachur NR 589
Baer MR 392
Bahler DW S2: 115
Bailey N S2: 141
Baker MA S1: 43
Balli AM 495
Ballatori E 437
Baral E 382
Barbounis V 769
Barnadas A 153

Avvisati G 405

Barni S 673 Barón FJ 151, 521, 751 Baronzio GF 196 Barr W 231 Bastion Y S2: 123 Basurto C 437 Batiste-Alentorn E 495 Baum M 532 Beattie GJ 755 Becquart D 377 Bellas C 443, 585 Bellmunt J 310 Beltrán M 495 Bennett MH S2: 83 Beretta A 673 Beretta GD 673 Berger DP 72 Berger F S2: 123 Bergmann L 197 Berná Ll 409 Bernacer B 310 Bernhard J 597 Bernier M 67 Bertelli G 575 Bertini M 733 Bettelheim R 47 Bianco C 169 Bisagni G 687 Blackledge G S2: 141 Blake PR 131 Bloomfield CD 392 Blume KG S1: 47 Boasson M 485 Body JJ 141 Bohr VA 325 Boiron M S2: 73 Bombino T 417 Bonadonna G 719, S1: 9, S2: 55, 645 Bonfante V S1: 9 Bonhomme L 234 Boni C 687 Bonmassar E 759 Boschetti E 437 Bosq J 431 Bracarda S 437 Brack N S2: 177

Brambilla C 417, 719

Bramwell VHC 689

Breed WPM S2: 63

Bregni M 645, S1: 9

Brittinger G S2: 177

Brosteanu O 579

Brown S S2: 115

Broder S 248, S2: 191

Bron D 67, 431, S1: 57

Broxterman HJ 55, 635

Brandalise S 441

Brice P S2: 73

Bryon P-A S2: 123 Buesa JM 151, 307, 521, 751 Bugat R 217 Buick S S1: 43 Bultinck J 694 Burgers JMV 431, S2: 63 Burt RK 325 Busquier I 130 Butow P 597 Butti G 63 Cabanillas F 25, S1: 31, S2: 137, S2: 213 Caillou B 431 Calabresi F 377, 727 Caliceti U 379 Calvert AH 89 Campbell MJ S2: 115 Canal P 217 Candel MT 310 Canellos GP S1: 1, S2: 213 Cantwell BMJ 71, 203 Capri G 719 Carbone A S2: 107 Carde P S2: 63, 431 Carella AM S2: 181 Carles J 153 Carnot J 33 Carrió I 409 Carver A 589 Casolati E 609 Catalán G 495 Cattan A 431 Cavalli F 7, 123, 168, 529, 621, 727 Cavallin-Ståhl E 739, S2: 99 Ceci G 687 Cerny T 727 Cervantes A 130 Cesana B 673 Chan S 571 Chang I-C S2: 151 Chao NJ S1: 47 Chatelut E 217 Chaturvedi SK 693 Chauvin F S1: 57 Chen TT S2: 115 Cheng A-L S2: 151 Chevreau C 217 Chisesi T S2: 181 Chiu E 156 Choi K 571 Christian MC 115 Ciardiello F 169 Clark P S2: 147 Clarkson BD S1: 51 Clerici M 446

Brunner KW 771

Coates A 597 Cocconi PG 9, 687 Coiffier B 619, S1: 57, S2: 123, S2: 213 Colombatti A S2: 107 Comella G 673 Congiu AM S2: 181 Connors JM S1: 17 Conti M 609 Contu A S2: 181 Cordiner J 231 Corrado C 33 Cortes-Funes H 9 Coser P S2: 181 Cosset JM 431, S2: 77 Costa A 446 Cotter FE 335, S2: 93, S2: 147 Cowie VJ 755 Cozzaglio L 673 Crespeigne N 589 Crippa F 719 Cristoni M 673 Crivellari D 145 Croce CM S2: 9 Crosato I 373 Crowther D 423, 505, 605, S2: 49,

Crowther D 423, 505, 605, S2: 4 S2: 141, S2: 207, S2: 213 Cruz Hernandez JJ 521 Cserhati MD 489 Cucchiara G 759 Cueva JF 521

D'Amico T S2: 181 D'Incalci M 63, 145, 635 Dalal BI 382 Dall'Olio D 379 Dallenbach F S2: 33, S2: 163 Damia G 145 Davies JM S2: 39 Davis CL S2: 147 de Forni M 217 de Graeff A 691 de Gramont A 229 de Pauw BE 431, S2: 63 de Valeriola D 589 de Wolf-Peeters C 431 De Bellis R 441 De Conno F 196, 610 De Filippi R 759 De Palo G 216, 446 De Sande LMG 751 De Vecchis L 759 Deakin DP 423, S2: 49, S2: 141 Del Favero A 107, 437 Del Vecchio L S2: 107 Delfau S 229 Demuynck B 229 den Engelse L 115 Desablens B 485

De Vita Jr VT 93, S1: 33

Di Blasio B 687

Dieterle A 69

Diehl V 579, S2: 43

Dilhuydy J-M 347

Dienemann D S2: 163

Dini D 575 Dirix L 377 Dixon D 25 Dodion PF 589 Dölken G 197 Dombernowsky P 41, 154 Donadio D 289 Donelli MG 63 Donnelly M 745 Dorey E S2: 147 Dornoff W S2: 177 Dorticos Bavea E 33 Dragoni F 365 Drings P 361 Duez N 431 Dunn S 597 Dupont B 289 Durand M 347 Durie BGM 166, S2: 207 Durr E S2: 137

Eary JF S2: 187 Ecstein E 234 Edwards RHT S2: 39 Egorin MJ 589 Einhorn LH 167 Eisenhauer EA 689, 772 Eissa S 137 Elattar I 137 Elsebai I 137 Enblad G 297 Engelhard M S2: 177 Enne W S2: 177 Eppinger-Helf M 33 Errante D 373 Esserman L S2: 115 Esteban E 151, 521, 751 Estorch M 409 Estrada E 151, 521, 751 Evans ML S2: 147 Exner GU 489

Faggiano F 559 Faintuch J 519 Falda M 191 Falkson CI 303 Falkson G 303 Falkson HC 303 Farquharson HA S1: 43 Favaro D 145 Felman P S2: 123 Ferme C S2: 73 Fernandez I 441 Fernandez-Muñoz R 585 Fernández OA 751 Fernández R 151 Ferrari L 417 Ferrer J 495 Fev MF 629, 771 Ffrench M S2: 123 Fiebig HH 72 Filiberti A 610 Findlay B 681

Fisher RI S1: 33
Foà R S2: 201
Fonseca E 521
Forbes JF 243
Formeli F 446
Forno G 575
Forrest A 589
Fosså SD 203
Franceschi S 395
Fredj G 234
Frija J S2: 73
Frontini L 673
Frost P 519
Fuggetta MP 759
Fuller LM 25, S2: 137

Gad El Mawla N 137 Gaetani P 63 Gallego O 310 Galligioni E 145 Gallo E 733 Gandola L 645 Gangeri L 417 Garcia-Conde J 130 Garcia J 310 Gardembas-Pain M 485 Garin AM 667 Gassmann W S2: 177 Gastaut JA 289 Gatzemeier U 213 Gause A 579, S2: 43 Gavosto F S2: 201 Gee T S1: 51 Gelber RD 47, 461, 745 Gentilini M 289 Gerard B 377 Gerhartz H S2: 177 Germá-Lluch JR 409 Ghandour Ch 485 Giannarelli D 212 Gianni AM 645, S1: 9 Gianni L 719, S1: 9 Gill I 115 Gisselbrecht C S1: 57, S2: 73 Glimelius B 297 Goddard PM 535 Goerg C 361 Goldhirsch A 47, 123, 320, 461 Golding PF 501 Gomez Bernal A 521 Gonzalez-Canali G 229 González Barón M 751 Goodlow J 681 Goss PE S1: 43 Gottardi O 673 Gracia JM 151, 521, 751 Gradishar WJ 383 Gratwohl A 69 Greco D 373 Greco M 719 Grilli R 216 Groscurth P 489

Groshen S 641

Groth G 213 Grunberg S 115 Guaraldi M 379 Guglielmi C 365, S1: 57 Gulati SC S1: 51, S2: 67 Gusterson BA 47

Habboubi N 137 Hadisaputro MMN 55 Hagemeister FB 25, S2: 137 Hagenbeek A 431, S1: 57, S2: 63 Haim N 311 Hallas J 223 Hallek M S2: 177 Hamilton JM 625 Hammershaimb L 589 Hamza MR 137 Hannibal J 223 Hansen HH 41, 355 Hansen M 41, 223 Harding MJ 203, 231 Hardy JR 131, 532 Harper P 131 Harrap KR 535 Harris AL 71 Harris M 423 Harstrick A 197 Hasenclever D 579, S2: 43 Häußingen K 213 Havemann K 361 Hayat M 431, S2: 63 Hayward RL 655 Heckmayr M 213 Heintz APM 691 Heise J S2: 177 Hendrick AM 71 Hennequin C S2: 73 Henry-Amar M S2: 63, S2: 77 Herbst H S2: 33 Herrstedt J 154, 223 Herweijer H 305 Hettchen W S2: 177

Henß H 72 Hietanen P 19 Hirsch FR 41, 355 Hochuli E 269 Hoff A 767 Hoffmann W 769 Hohnloser J 197 Hole D 231 Holland J 8 Holmes L S2: 137 Honegger HP 489, 530 Hoppe RT S1: 47 Horning SJ S1: 47 Horton M S2: 147 Hoskins P S1: 17 Houin G 217 Houts P 511 Howells N 607 Hubbard SM S1: 33 Huhn D S2: 177 Hürny C 597

I Ibrahim EM 517 Imburgia L 123 Izquierdo A 495

J Janson R 769 Jasmin C 234 Jeffery GM 501 Jeppesen BH 154 Jimeno J 310 Johnson A 739, S2: 99 Johnson NP 217 Johnson RJ 423 Johnston D 681 Jones WG 203 Jordan VC 481

Kabelitz K S2: 177 Kagan J S2: 9 Kaizer L 681 Kajanti MJ 765 Kantrowitz JD 589 Kaye SB 203, 231, 727 Keizer HJ 203 Kennedy J 231 Kerger J 589 Khaled H 137 Khlebnov AV 667 Kim N 169 Klastersky J 454 Klijn JGM 183 Klimo P S1: 17 Kluin-Nelemans JC 431, S1: 57 Knerich R 63 Knowling M 689 Köhne-Wömpner C-H 197 Kortes V 115 Kratzsch H-C S2: 33 Krulik M 229 Kruschwitz M S2: 163 Kuiper CM 55 Kuse R S2: 177

L La Vecchia C 395 Laberge F 681 Labianca R 383, 673 Lacave AJ 151, 521, 751 Lacor P 694 Lagadec B 229 Lambert HE 607 Lammers U 197 Lamy Th 485 Lang JM 234 Larsson LI 355 Latreille J 681 Laudadio P 379 Laursen LC 223 Lazzarin A 373, 609 Lengfelder E S2: 177 Lennert K S2: 177

Kwak LW S1: 47, S2: 115

Leonard RCF 655, 755 Levis A 191, 733 Levy R S2: 115 Levy S S2: 115 Lewis CR 203 Liang R 40, 156 Liati P 727 Liberati A 216, 273 Liberati MC 273 Lichtman S 522 Lim J S2: 147 Link Jr CJ 325 Liscia DS 169 Lister TA 707, S2: 131, S2: 141, S2: 147 Livingstone JRB 755 Llombart A 130 Lluesma-Goñalons M 33 Lofters WS 681 Loke SL 40, 156 Lombardi F 645, S1: 9 Long GD S1: 47 Longo DL S1: 33 Lönnqvist J 19 López R 521 Louvet C 229 Love R 523 Ludwig F S2: 177 Luini A 719 Lund B 281 Lupattelli M 437

Macchiavello F 575 MacCormick R 772 MacLennan KA S2: 83 Magnussen H 213 Magrath IT 137, S2: 219 Maino E 610 Maisani J-E 229 Maloney DG S2: 115 Mandelli F 365, 405 Mansour MA 137 Marcuello E 409 Marini S 759 Marmont F 191 Marolleau JP S2: 73 Marsoni S 245 Martelli M 365 Martignoni G 673 Martin Garcia G 521 Martinelli G 123 Martínez J 443 Martoni A 379 Mathijs R 694 Mauriac L 347 McGeady ML 169 McLaughlin P 25, S2: 137 McQuade B 607 Mead GM 203, 501 Medina da Cunha F 443 Meerabux J S2: 93

Luporini G 383, 673

Luxi G 733

Lustman-Marechal J 431

- Meerwaldt JH 431, S2: 77 Mele A 405 Meneghini V 733 Mermillod B 9 Mertelsmann R 251 Meusers P S2: 177 Meuthen I S2: 177 Meyer CJLM 55 Meyer P 234 Meyerowitz BE 273 Michael C 115 Mikhina ZP 667 Milella G 437 Mill L 203 Miller RA S2: 115 Miller TP S1: 33 Milsted R 231 Misset JC S1: 57 Misset JL 234 Molchanov GV 667 Monconduit M 431, S2: 63 Monfardini S 145, 373, S2: 107, S2: 201 Monsuez JJ S2: 73 Montalban C 585 Mor V 511
- Montalban C 585 Mor V 511 Morales S 310 Moritz T S1: 25 Morlat P 289 Moroni M 373 Mosconi P 273 Mouridsen HT 307 Mueller N 52: 23 Muggia FM 115, 641 Muggiasca ML 609 Murphy SB S2: 219
- Nagel-Hiemke M S1: 25 Nasirova RJ 667 Natt F 197 Negretti E S2: 55 Negrin RS S1: 47 Neijt JP 691 Neuhauss R 213 Neville AM 13 Niederle N S1: 25 Niedobitek G S2: 33 Niemeyer CM 745 Nissen-Meyer R 343 Nogueras FM 409 Noordijk EM 431 Nooter K 305 Nordlinger B 229 Nørgaard P 541 North L 25 Norton A S2: 141, S2: 147 Novarino A 733 Novero D 733
- Nunziata C 759

  O
  O'Brein S 522
  O'Connor P S1: 47

O'Reilly SE S1: 17

Nowrousian MR S1: 25

- Obrecht JP 69
  Obrist R 69
  Occhiuzzi L 379
  Ojeda MB 495
  Oliver RTD 87
  Oosterom R 305
  Oren R S2: 115
  Orsucci L 733
  Osoba D 681
  Østerlind K 41
- Palacio I 151, 521, 751 Palau V 441 Pancera G 673 Pannuti F 379 Parker RJ 115 Parravicini C 609 Pasquini P 405 Passalacqua R 687 Pater J 681 Paul J 203 Pavel JV 213 Pavlovsky S 33, 441 Pectasides D 769 Pedersen AG 41 Perren TJ 131 Peters GJ 469
- Peters GJ 469
  Pfreundschuh M 579, S2: 43
  Philip T S1: 57
  Piccart M 589
  Picciafuoco M 437
  Pic6 C 495
  Pierluigi D S2: 181
  Pieters R 55
  Pietrangeli A 212
  Pinedo HM 55, 703
  Pinto A S2: 107
  Pizzuti M 733
  Planting A 767

Pluda JM 248, S2: 191

Plusquellec Y 217

- Poirier MC 325 Poliwoda H 197 Pollera CF 212 Porcellini A S2: 181 Poveda A 307 Preger P 443 Prescott RJ 655 Prete SP 759
- Price CGA S2: 93, S2: 141, S2: 147 Pyrhönen SO 765
- Q Quaia M 145 Quirt IC 689
- R
  Raber MN 519
  Radford JA 423, 505, S2: 49
  Radtke H S2: 177
  Rageth JC 269
  Rajewsky MF 565
  Ranson MR 423
  Raphael M 289

- Rastogi R 589 Ratain MJ 522 Räth U 197 Raveis VH 511 Redman JR 25, S2: 137 Reed E 115 Regnier R 431 Reichhardt P 197 Reiter A 745 Resegotti L 191, 733 Ribelles N 153 Ricci F 759 Richard V 67 Richards MA 663 Riehm H 745 Rifá J 495 Ripamonti C 196, 610 Ritz R 69 Rizzoli V S2: 181 Roberts AB S2: 207 Robinson E 311 Roche H 217 Rodenburg CJ 203, 305 Rodriguez MA 25 Rodríguez-García JL 443, 585 Rohatiner AZS S2: 141, S2: 147 Roila F 107, 437 Roithmann S 289 Roncadin M S2: 107 Roschansky V 579, S2: 43 Rosell R 153 Rosen G 456 Rosenberg SA S2: 29 Rossei E S2: 181 Rossi C 63 Rosso S 417 Rubens RD 663 Ruiz-Arguelles G 441 Rusthoven J 681 Rustin GJS 607
- Sabbioni MEE 244 Saeki T 169 Saita L 196, 610 Saletan S 589 Salgado G 443 Sallan SE 745 Salomon DS 169 Samuels BL S2: 1 Sanchez P 521 Sánchez-Corral J 443 Santarelli MT 33, 441 Santini G S2: 181 Santoro A S1: 9, S2: 55 Sassi M 437 Scapaticci R 673 Scarpati D S2: 181 Schacter BA 382 Schadeck C S2: 177 Scheffer GL 55 Scheper RJ 55 Schmidt CG S1: 25 Schmits R 579, S2: 43

Ryder WDJ S2: 49

Schmoll H-J 197, 623 Schneider M 9 Schöber C S2: 177 Schumacher E S2: 177 Schwartsmann G 443, 703 Scott JG S1: 43 Sculier J-P 67, 141 Seeber S 9, 769, S1: 25 Segal F 443 Sellin RV 709 Sensebe L 485 Serraino D S2: 107 Serrano M 443 Sertoli R S2: 181 Sessa C 123, 727 Setter M 571 Seymour AM 695 Seynaeve C 305 Shepherd FA 772, S1: 43 Shimoyama M S2: 157 Shipp MA S2: 213 Sholokhov VN 667 Siegel K 511 Siegert W 197, S2: 177 Siena S 645, S1: 9 Silvani V 63 Silveira LA 443 Silvermintz K 25 Sizer B 445 Skov BG 355 Skovgaard Poulsen H 541 Skovsgaard T 727 Slevin M 131 Smaldone L 681 Smart GE 755 Smerieri F 673 Smith DB 605, 607 Smith K S2: 43 Smith P 663 Smith SR S2: 39 Smyth JF 755 Sokolov VA 667 Solano V 153 Somers R 431, S1: 57, S2: 63 Sørensen JB 355 Sörenson S 41 Sorio R 145, 727 Souhami RL 15, 323 Soukop M 203, 231 Soutter WP 231 Spada A 145 Spagnolli P 673 Spina M 373 Splinter T 203 Sporn MB S2: 207 Staiger H-J S2: 177

Stallbaum B S1: 47

Stein H 177, S2: 33, S2: 163

Stazi MA 405

Sterlini J S2: 147 Steward W 307, S2: 141

Steward WP 605

Stewart ME 755

Stock W 522

Stoll BA 401

Stoter G 305, 767 Struyf N 694 Su I-J S2: 151 Sumrall C 519 Sundström C 297 Sutcliffe S S1: 43 Sutton D S1: 43 Swan F 25, S2: 137 Swindell R 423 Sylvester R 307 Szekely AM 234

T Taillan B 289 Takahashi S S2: 115 Talamini R 145 Tamburini M 417 Tambussi G 609 Tan S 131 Tanguy A 431 Tarayre M S2: 63 Tarella C 733 ten Bokkel Huinink W 203 Terhardt E S2: 177 Terheggen PMAB 115 Tessen H-W 361 Themelin L 67 Theodore C 289 Thereza MS 443 Theriault RL 709 Thiel E S2: 177 Thomas D 307 Thomas J 431, S2: 63 Thomas M S2: 177 Tiemann M S2: 177 Tilly H 289 Tirelli U 373, S2: 201 Tjia P 691 Tjulandin SA 667 Tobler A 629 Todeschini G 733 Toledano M 289 Tomatis L 265 Tonato M 107, 437 Tononi A 379 Tourani JM 289 Tredaniel J S2: 73 Trumbic B 234 Tschiersch A 579, S2: 43 Tubiana M 431 Turriziani M 759

U Ultmann JE S2: 1 Umetsu DT S2: 115 Unger C 269 Urgesi A 733

Twelves CJ 15, 663, 695

Tusquets I 495

V Vaccher E 373, S2: 201 Vago L 609 Valagussa P 320, 645, S1: 9, S2: 55 Valenti MR 535

Valsecchi MG 245 van der Burg M 767 van der Schueren E 431 van der Valk P 55 van Glabbeke M 431 van Groeningen CJ 469 van Heerde P 431 van Hoef MEHM 691 van Kalken CK 55, 635 van Oosterom AT 203, 307 van Unnik JAM 431 Van den Weyngaert D 694 Van Echo DA 522 Vandenberg T 681 Vanderlely J S1: 57 Varette C 229 Vaughan Hudson B S2: 83 Vaughan Hudson G S2: 83 Veerman AJP 55 Vegna ML 405 Velasquez WS 25, S2: 137 Ventafridda V 196, 693 Venturini M 575 Verdonck L S2: 63 Veronesi U 446 Verpoort K 579 Verweij J 305, 307, 767 Vestlev PM 307 Vetrova NA 667 Villani F 719 Villar-Grimalt A 310 Vinante O S2: 181 Vinci M 673 Vineis P 559 Vinholes J 443 Vitolo U 733 Viviani S S1: 9, S2: 55 Vogelzang NJ 522 Vokes EE 383 Volpe R S2: 107 von Hochstetter A 489 von Rohr A 771 Vose JM S2: 171

Wagener DJT 9, 307, 431 Wagner T S2: 177 Wang J-X 655 Warner E S1: 43 Warr D 681 Weidmann B 769 Wery F 589 Whitehouse JMA 9 Whitmarsh K S1: 51 Wierzbicki R 689 Wilke H 197 Wilkinson PM 423 Willems MG S2: 177 Williams CE S2: 39 Williamson P 281 Wilmanns W S2: 177 Wils J 377 Wilson K 681 Wiltshaw E 131

Winterhalter BR 72

Wolf M 361 Wyss P 269

Y Yahalom J 67, S1: 51 Yarchoan R 248, S2: 191 Young BD S2: 93 Young RC S1: 33 Z Zaccarelli M 373 Zadro A 673 Zagonel V S2: 107 Zaniboni A 673 Zanini M S2: 55 Zee B 681 Zelenetz AD S2: 115 Zimmermann A 771 Zittoun R S2: 63 Zucali R S1: 9, S2: 55 Zucca E 335, S2: 93 Zucchetti M 63 Zwingers T S2: 177

